Leptomeningeal carcinomatosis - Presenting features and prognostic factors

被引:203
作者
Balm, M
Hammack, J
机构
[1] Department of Neurology, Mayo Clinic, Rochester, MN
[2] Neurology Department, Mayo Clinic, Rochester, MN 55905
关键词
D O I
10.1001/archneur.1996.00550070064013
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine factors that are predictive of survival among patients with leplomeningeal carcinomatosis. Background: Studies of potential prognostic factors in leptomeningeal carcinomatosis have produced conflicting results. Reasons for the discrepancies may be methodological differences in case ascertainment, treatment protocols, and limitations due to the size of the study group. Design and Methods: We reviewed the medical records of 126 patients with cytologically confirmed leptomeningeal carcinomatosis seen at the Mayo Clinic in Rochester, Minn, from 1983 to 1994. Clinical, radiographic, and cerebrospinal fluid (CSF) parameters at the time of presentation are summarized. Treatment response, complications, and cause of death are also discussed. Using the forward stepwise Cox model, independent predictors of survival were identified. Results: Independent negative predictors of survival include elevated CSF protein (P<.001) and clinical involvement of the cerebral leptomeninges (P=.05). Independent positive predictors of survival were longer duration of neurological symptoms at the time of presentation (P<.005), treatment with intrathecal or intraventricular (intra-CSF) chemotherapy (P=.01), and female sex (P=.02). Other variables, including age, primary tumor type, and extent of systemic disease, were not predictive. Conclusions: We conclude that female sex, longer duration of neurological symptoms, absence of cerebral leptomeningeal clinical involvement, and absence of elevated CSF protein independently predict better survival. Patients created with intra-CSF chemotherapy also survived longer.
引用
收藏
页码:626 / 632
页数:7
相关论文
共 51 条
  • [1] AMER MH, 1978, CANCER, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO
  • [2] 2-E
  • [3] MENINGEAL CARCINOMATOSIS IN SMALL CELL-CARCINOMA OF THE LUNG
    ARONEY, RS
    DALLEY, DN
    CHAN, WK
    BELL, DR
    LEVI, JA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1981, 71 (01) : 26 - 32
  • [4] CREATINE KINASE-BB IN THE CEREBROSPINAL-FLUID AS A MARKER OF CNS METASTASES AND LEPTOMENINGEAL CARCINOMATOSIS IN PATIENTS WITH BREAST-CANCER
    BACH, F
    BACH, FW
    PEDERSEN, AG
    LARSEN, PM
    DOMBERNOWSKY, P
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (12): : 1703 - 1709
  • [5] BACH F, 1993, CANCER, V72, P2376, DOI 10.1002/1097-0142(19931015)72:8<2376::AID-CNCR2820720814>3.0.CO
  • [6] 2-6
  • [7] Beerman WF, 1912, J AMER MED ASSOC, V58, P1437
  • [8] BOOGERD W, 1991, CANCER, V67, P1685, DOI 10.1002/1097-0142(19910315)67:6<1685::AID-CNCR2820670635>3.0.CO
  • [9] 2-M
  • [10] LEPTOMENINGEAL METASTASIS - A COMPARISON OF GADOLINIUM-ENHANCED MR AND CONTRAST-ENHANCED CT OF THE BRAIN
    CHAMBERLAIN, MC
    SANDY, AD
    PRESS, GA
    [J]. NEUROLOGY, 1990, 40 (03) : 435 - 438